ReviewCardiology clinics2010
The genetics of vascular complications in diabetes mellitus.
Review in Cardiology clinics, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 41 citations in OpenAlex.
- Contribution of haptoglobin phenotypic variation to the presence of hyperhomocysteinemia in type 2 diabetics with and without angiopathy.European journal of clinical nutrition · 2025Article
- Human Paraoxonase 1: From Bloodstream Enzyme to Disease Fighter & Therapeutic Intervention.Current protein & peptide science · 2025Review
- Evaluation of serum haptoglobin levels and Hp1-Hp2 polymorphism in the haptoglobin gene in patients with atrial fibrillation.Molecular biology reports · 2022Article
- Association of paraoxonase 1 activity and insulin resistance models in type 2 diabetes mellitus: Cross-sectional study.Journal of the Chinese Medical Association : JCMA · 2022Article
- Association of NOS3 (rs 2070744) and SOD2Val16Ala (rs4880) gene polymorphisms with increased risk of ESRD among Egyptian patients.Journal, genetic engineering & biotechnology · 2021Article
- The Role of Nutrients in Reducing the Risk for Noncommunicable Diseases during Aging.Nutrients · 2019Review
- Haptoglobin levels, but not Hp1-Hp2 polymorphism, are associated with polycystic ovary syndrome.Journal of assisted reproduction and genetics · 2017Article
- Analysis of a cardiovascular disease genetic risk score in the Diabetes Heart Study.Acta diabetologica · 2015Article
- Identifying Common Genetic Risk Factors of Diabetic Neuropathies.Frontiers in endocrinology · 2015Review
- Poor lysosomal membrane integrity in proximal tubule cells of haptoglobin 2-2 genotype mice with diabetes mellitus.Free radical biology & medicine · 2012Article
- The 4a/4a genotype of the VNTR polymorphism for endothelial nitric oxide synthase (eNOS) gene predicts risk for proliferative diabetic retinopathy in Slovenian patients (Caucasians) with type 2 diabetes mellitus.Molecular biology reports · 2012Article
- Haptoglobin 2-2 genotype is associated with increased risk of type 2 diabetes mellitus in northern Chinese.Genetic testing and molecular biomarkers · 2012Article
- Haptoglobin genotype predicts development of coronary artery calcification in a prospective cohort of patients with type 1 diabetes.Cardiovascular diabetology · 2011Article
- Intraplaque haemorrhages as the trigger of plaque vulnerability.European heart journal · 2011Review
- Genetics of redox systems and their relationship with cardiovascular disease.Current atherosclerosis reports · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Prospective identification of which individuals with diabetes mellitus (DM) are at greatest risk for developing cardiovascular disease (CVD) complications would have considerable public health importance by allowing the allocation of limited resources to be focused on those individuals who would most benefit from aggressive intervention. Over the past 20 years genetic disease association studies have demonstrated that polymorphisms at specific genetic loci may identify those individuals at greatest risk for developing CVD in the setting of DM. This article reviews the evidence accumulated to date on four polymorphic loci with the aim of explaining how these polymorphisms modify the risk for CVD in DM by modifying the functional activity of a specific gene. Use of the knowledge of these genetic differences among individuals in targeting drug therapy (pharmacogenomics) is also discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.